Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Schumann

Showing results (71-80 of 102) with videos related to

Pageof 11
Sort By:
Translational Lung Cancer Research|November 17, 2022
Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADOChristian Grohé, Thomas Wehler, Tobias Dechow, et al.
Pharmacogenomics|October 13, 2012
HLA polymorphisms influence the development of skin rash arising from treatment with EGF receptor inhibitorsDaniel Fuerst, Sumit Parmar, Christian Schumann, et al.
Lung Cancer (Amsterdam, Netherlands)|October 30, 2020
Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)Martin Faehling, Christian Schumann, Petros Christopoulos, et al.
Data in Brief|December 28, 2020
Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAPMartin Faehling, Christian Schumann, Petros Christopoulos, et al.
Respiratory Care|February 1, 2011
Superior vena cava syndrome in thoracic malignanciesPhilipp M Lepper, Sebastian R Ott, Hanno Hoppe, et al.
Oncotarget|May 20, 2021
Association between miRNA signatures in serum samples from epidermal growth factor inhibitor treated patients and skin toxicitySarah Kemski, Vivien Molitor, Michael Steffens, et al.
Lung|April 9, 2013
Histology as a potential clinical predictor of outcome in advanced non-small-cell lung cancer treated with vinorelbine and mitomycin combination chemotherapyThomas Wibmer, Thierry Berghmans, Cornelia Kropf-Sanchen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 14, 2015
EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational studyWolfgang Schuette, Peter Schirmacher, Wilfried Ernst Erich Eberhardt, et al.
Pharmacogenomics|October 1, 2015
High-throughput screening identified inherited genetic variations in the EGFR pathway contributing to skin toxicity of EGFR inhibitorsSayed-Mohammad Hasheminasab, Mladen V Tzvetkov, Christian Schumann, et al.
Innovative Surgical Sciences|October 4, 2019
Navigation and visualisation with HoloLens in endovascular aortic repairVerónica García-Vázquez, Felix von Haxthausen, Sonja Jäckle, et al.
Pageof 11

Showing results (71-80 of 102) with videos related to

Sort By:
Pageof 11
Translational Lung Cancer Research|November 17, 2022
Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADOChristian Grohé, Thomas Wehler, Tobias Dechow, et al.
Pharmacogenomics|October 13, 2012
HLA polymorphisms influence the development of skin rash arising from treatment with EGF receptor inhibitorsDaniel Fuerst, Sumit Parmar, Christian Schumann, et al.
Lung Cancer (Amsterdam, Netherlands)|October 30, 2020
Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)Martin Faehling, Christian Schumann, Petros Christopoulos, et al.
Data in Brief|December 28, 2020
Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAPMartin Faehling, Christian Schumann, Petros Christopoulos, et al.
Respiratory Care|February 1, 2011
Superior vena cava syndrome in thoracic malignanciesPhilipp M Lepper, Sebastian R Ott, Hanno Hoppe, et al.
Oncotarget|May 20, 2021
Association between miRNA signatures in serum samples from epidermal growth factor inhibitor treated patients and skin toxicitySarah Kemski, Vivien Molitor, Michael Steffens, et al.
Lung|April 9, 2013
Histology as a potential clinical predictor of outcome in advanced non-small-cell lung cancer treated with vinorelbine and mitomycin combination chemotherapyThomas Wibmer, Thierry Berghmans, Cornelia Kropf-Sanchen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 14, 2015
EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational studyWolfgang Schuette, Peter Schirmacher, Wilfried Ernst Erich Eberhardt, et al.
Pharmacogenomics|October 1, 2015
High-throughput screening identified inherited genetic variations in the EGFR pathway contributing to skin toxicity of EGFR inhibitorsSayed-Mohammad Hasheminasab, Mladen V Tzvetkov, Christian Schumann, et al.
Innovative Surgical Sciences|October 4, 2019
Navigation and visualisation with HoloLens in endovascular aortic repairVerónica García-Vázquez, Felix von Haxthausen, Sonja Jäckle, et al.
Pageof 11